P297 SUSTAINED RELEASE NICOTINIC ACID VERSUS INOSITOL HEXANICOTINATE FOR THE TREATMENT OF DYSLIPIDEMIABookdoi:10.1016/S1567-5688(10)70364-0J. KeenanElsevier Ireland LtdAtherosclerosis Supplements
Sustained-release nicotinic acid vs inositol hexanicotinate for the treatment of dyslipidemiaKeenan, J M
Bookdoi:10.1016/j.jacl.2010.03.047Joseph KeenanJournal of Clinical LipidologyKeenan J. Extended-release nicotinic acid versus inositol hexanicotinate for the treatment of dyslipidemia. J Clin Lipidol. 2010;4:216-217.
P297 SUSTAINED RELEASE NICOTINIC ACID VERSUS INOSITOL HEXANICOTINATE FOR THE TREATMENT OF DYSLIPIDEMIAdoi:10.1016/s1567-5688(10)70364-0J. KeenanElsevier BVAtherosclerosis Supplements
Lowering Cholesterol with Niacin: Nicotinic Acid, Nicotinamide, and Inositol HexanicotinateKlingman, Kip
A cross-over trial was run to compare the effects of two delayed-action nicotinic acid polyesters (pentaerythritol-tetranticotinate, PETN, and inositol-hexanicotinate, MIEN) in 59 aged normo- and dyslipaemic subjects. PETN tended to normalise the lipid picture in much the same way as nicotin...
(2013) Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemia. Journal of Clinical Lipidology 7 , 14-23 /...